TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Reduction of Bacteriuria in Subjects Practicing Intermittent Catheterization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of informed consent~* Female/male aged 18 years and over~* Practicing intermittent catheterization at least 4 times daily for at least 6 weeks~* A minimum of 104 CFU of bacteriuria~Exclusion Criteria:~* Ongoing, symptomatic UTI at enrollment~* Known urethral stricture~* Basic tumorous disease~* Previous prostate surgery~* Subjects known to be immunocompromised e.g. HIV or diabetes~* Treatment with antibiotics and/or intravesical antiseptics for the past 30 days before study start~* Involvement in the planning and conduct of the study (applies to both Astra Tech staff or staff at the study site)~* Pregnancy or breast feeding~* Previous enrolment or randomisation of treatment in the present study~* Participation in a clinical study that possibly might interfere with the present study, as deemed by the investigator~* Severe non-compliance to protocol as judged by the investigator and/or Astra Tech

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Catheter A (Type: EXPERIMENTAL): Catheterization with Catheter A, which releases silver ions into the urethra and urinary bladder upon catheterization,.~After activation in the wetting solution the coating retains water creating a smooth liquid surface around the catheter.The products are intended for single use. No additional lubricant were used.~The subject will be treated with investigational products during 24 hours. During this period the subject will be catheterized with the study catheter at six occasions (every 4 hours).
- Catheter B (Type: EXPERIMENTAL): Catheterization with Catheter B, which releases both silver ions and degradable silver particles.. After activation in the wetting solution the coating retains water creating a smooth liquid surface around the catheter.The products are intended for single use. No additional lubricant were used.~The subject will be treated with investigational products during 24 hours. During this period the subject will be catheterized with the study catheter at six occasions (every 4 hours).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Role of Tapering Pace and Selected Traits on Hypnotic Discontinuation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. be currently using one or more BZD or newer BzRA hypnotics at bedtime for insomnia management;~2. have been using one or more such agents at least 5 nights per week for at least the past 12 months;~3. express interest in discontinuing hypnotic use and learning to manage their insomnia without medications;~4. report one or more failed attempts to discontinue hypnotic use in the past;~5. provide written consent to participate.~6. have an insomnia severity index score \> 10 indicating at least mild insomnia symptoms without sleep medication~Exclusion Criteria:~1. an untreated unstable, or in-treatment psychiatric disorder (e.g., major depression in psychotherapy or on a medication regimen that has been changed within the past 2 months)~2. a lifetime diagnosis of any psychotic or bipolar disorder~3. an imminent risk for suicide~4. evidence of alcohol or drug abuse (other than hypnotics) within the past year, since such abuse patterns suggest specialized substance abuse treatment may be indicated~5. unstable or terminal physical illness (e.g., cancer), neurological degenerative disease (e.g., dementia) or sleep disruptive medical condition (e.g. chronic pain)~6. current use of medications known to cause insomnia (e.g., corticosteroids)~7. a history or screening evidence of restless legs syndrome, circadian rhythm sleep disorder (e.g., delayed sleep phase syndrome), sleep apnea (AHI \> 5), or periodic limb movement disorder (PLM index \> 15)~8. habitual bedtimes later than 2:00 AM or rising times later than 10:00 AM; (i) consuming \> 2 alcoholic beverages per day at least 5 times per week~9. pregnant women or mothers with care-taking responsibilities for infants due to the sleep-disruption caused by such circumstances.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 0% Hypnotic Medication Taper (Type: SHAM_COMPARATOR): In this condition patients will be maintained on their baseline hypnotic medication dosage throughout a 20-week double-blinded tapering period.
- 25% Hypnotic Medication Taper (Type: ACTIVE_COMPARATOR): In this condition patients will have their current hypnotic medication dosage reduced by 25% every 2 weeks throughout a 20-week double-blinded tapering period.
- 10% Hypnotic Medication Taper (Type: ACTIVE_COMPARATOR): In this condition patients will have their current hypnotic medication dosage reduced by 10% every 2 weeks throughout a 20-week double-blinded tapering period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Compare a Hemostatic Powder TC-325 and Standard Treatment in the Control of Acute Upper Gastrointestinal Bleeding From Nonvariceal Causes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients with overt signs of upper gastrointestinal bleeding (hematemesis, melena and/or circulatory instability)~* documented bleeding (Forrest I) from a non-variceal upper gastrointestinal source (gastro-duodenal ulcers, Mallory Weiss tear, cancers, Dieulafoy's and other vascular lesions) at endoscopy.~Exclusion Criteria:~* without a full informed consent from the patient or his next of kin~* Age \<18 years~* Pregnant~* Lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- TC-325 (Type: EXPERIMENTAL): Endoscopic Application of a Hemostatic Powder TC-325, \<=150gm , once
- standard treatment (Type: ACTIVE_COMPARATOR): standard treatment of either hemo-clipping or thermo-coagulation with or without pre injection with diluted epinephrine \<=20 clip or4 pulse , once only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Presents with chronic plaque psoriasis based on a confirmed diagnosis of chronic psoriasis for at least 6 months prior to randomization~* At least 10% Body Surface Area (BSA) of Psoriasis at screening and at randomization~* Static Physician Global Assessment (sPGA) score of at least 3 and Psoriasis Area and Severity Index (PASI) score of at least 12 at screening and at randomization~* Candidate for phototherapy and/or systemic therapy~* Men must agree to use a reliable method of birth control or remain abstinent during the study~* Women must agree to use reliable birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment~Exclusion Criteria:~* Pustular, erythrodermic, and/or guttate forms of psoriasis~* History of drug-induced psoriasis~* Prior use of etanercept~* Clinically significant flare of psoriasis during the 12 weeks prior to randomization~* Concurrent or recent use of any biologic agent~* Received non-biologic systemic psoriasis therapy or phototherapy (including psoralens and ultraviolet A \[PUVA\], ultraviolet B \[UVB\]) within the previous 4 weeks; or had topical psoriasis treatment within the previous 2 weeks prior to randomization~* Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to randomization and during the study~* Have participated in any study with interleukin 17 (IL-17) antagonists, including ixekizumab~* Serious disorder or illness other than plaque psoriasis~* Serious infection within the last 3 months~* Breastfeeding or nursing (lactating) women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for ixekizumab administered by two SC injections at Week 0, then one SC injection per Dosing Regimen 1 until Week 12. Placebo for etanercept administered by one SC injection twice weekly starting at Week 0 up to Week 12. At Week 12, participants are assigned to Dosing Regimen 2.
- 50 mg etanercept (Type: ACTIVE_COMPARATOR): Administered by SC injections twice weekly starting at Week 0 up to Week 12. At Week 12, arm is assigned to Dosing Regimen 2
- 80 mg ixekizumab Dosing Regimen 2 (Type: EXPERIMENTAL): Administered by two 80 mg SC injections at Week 0, then one 80 mg SC injection per Dosing Regimen 2 until Week 264.
- 80 mg ixekizumab Dosing Regimen 1 (Type: EXPERIMENTAL): Administered by two 80 milligram (mg) subcutaneous (SC) injections at Week 0, then one 80 mg SC injection per Dosing Regimen 1 until Week 12. At Week 12, arm is assigned to Dosing Regimen 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Fecal Microbiota Transplantation as add-on Therapy in Mild-to-moderate Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-60;~* Endoscopically and morphologically confirmed UC;~* Negative results of stool culture for the presence of pathogenic bacteria (Shigella spp., Salmonella spp., Campylobacter spp., Yersinia spp.) and toxin-producing Clostridioides difficile;~* partial Mayo score of 4-6;~* Mayo endoscopic subscore ≥1;~* Fecal calprotectin \> 150 mcg/g~* Treatment with mesalazine at a daily dose of 3 g during the last 4 weeks~Exclusion Criteria:~* Pregnancy, planning pregnancy or breastfeeding;~* Postponed operations on the abdominal cavity;~* Severe mental disorders, alcohol or drug abuse;~* Use of systemic corticosteroids, biological agents, and probiotics within 8 weeks before study~* Any condition or circumstance that would, in the opinion of the investigator, prevent completion of the study or interfere with analysis of study results.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- standard care group (Type: ACTIVE_COMPARATOR): mesalazine (Pentasa) at a daily dose of 3 g (2 g orally + 1 g rectally)
- Fecal transplantation (Type: EXPERIMENTAL): Fecal transplantation of fresh prepared feces from healthy donor. Application by colonoscope in proximal half of colon.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria: - Male or female, age greater than or equal to 18 years ( for Japan and Taiwan: age greater than or equal to 20 years) at the time of signing informed consent - Type 1 Diabetes Mellitus (based on clinical judgement and/or supported by laboratory analysis as per local guidelines) 12 months or more prior to screening - Currently treated with a basal-bolus insulin regimen for at least 12 months prior to screening (Visit 1) - Currently treated with a basal insulin analogue for at least 4 months prior to screening (Visit 1) - HbA1c 7.0-9.5% (53-80 mmol/mol) (both inclusive) as assessed by central laboratory - Body Mass Index less than or equal to 35.0 kg/m\^2 Exclusion Criteria: - Within the past 180 days any of the following: myocardial infarction, stroke or hospitalization for unstable angina and/or transient ischemic attack - Subjects presently classified as being in New York Heart Association (NYHA) Class IV Currently planned coronary, carotid or peripheral artery revascularisation - Diabetic ketoacidosis requiring hospitalisation within the last 180 days prior to screening (Visit 1) - Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of three months before screening (Visit 1)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mealtime faster-acting insulin aspart and insulin degludec (Type: EXPERIMENTAL): None
- Mealtime NovoRapid® and insulin degludec (Type: ACTIVE_COMPARATOR): None
- Postmeal faster-acting insulin aspart and insulin degludec (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed primary adenocarcinoma of the rectum that begins within 15cm of the anal verge as determined by sigmoidoscopy or colonoscopy~* Clinical T3 or T4 tumors as determined by endoscopic ultrasound and/or rectal MRI~* ECOG performance status of 0-2~* 18 years of age or older~* Creatinine of \< 2.0~* Adequate hepatic function~* Adequate hematopoietic function~* Use of effective means of contraception in subjects of child-bearing potential~Exclusion Criteria:~* Evidence of metastatic disease as determined by chest/abdominal/pelvic CT or physical exam~* Prior chemotherapy or radiation therapy for treatment of colorectal cancer~* Prior treatment with 5-FU~* Prior treatment with a tyrosine kinase inhibitor, EGFR inhibitor, or VEGF inhibitor~* Patients must not be receiving any other investigational agent~* Prior malignancy within the last 5 years except for completely excised skin cancer, in situ cervical cancer~* Warfarin anticoagulation~* Co-existent malignant disease~* Current or recent participation in a clinical trial (within 4 weeks from the first day of treatment)~* Pregnancy~* Blood pressure of \>150/100 mmHg~* Unstable angina~* NYHA Grade II or greater congestive heart failure~* History of myocardial infarction within 6 months~* History of stroke within 6 months~* Clinically significant peripheral vascular disease~* Evidence of bleeding diathesis or coagulopathy~* Presence of central nervous system or brain metastases~* Major surgical procedure, open biopsy, or significant trauma injury within 28 days prior to day 0, anticipation of need for major surgical procedure during the course of the study~* Minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to day 0~* Pregnant or lactating~* Urine protein:creatinine ratio \> or equal to one at screening~* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to day 0\]~* Serious, non-healing wound, ulcer, or bone fracture

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemotherapy and radiation (Type: EXPERIMENTAL): Continuous infusion 5-fluorouracil 225 mg/M2/d, bevacizumab 5 mg/kg IV q 14 days, erlotinib 50-150 mg orally daily for duration of radiation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sildenafil in Single Ventricle Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 3 months; ≤120 months.~2. History of congenital heart disease with severe hypoplasia of a right or left ventricle.~3. Undergoing cardiac catheterization as part of standard clinical care.~4. Availability and willingness of the parent/legally authorized representative to provide written informed consent.~Exclusion Criteria:~1. History of serious adverse event related to sildenafil administration.~2. History of sildenafil exposure within 48 hours of the study.~3. Presence of pulmonary venous obstruction.~4. Treatment with organic nitrates or alpha blockade therapy.~5. Contraindication to cardiac catheterization as determined by the attending cardiologist and including:~   1. Significant hemodynamic instability.~  2. Sepsis.~  3. Need for Extra-Corporeal Membrane Oxygenation (ECMO) support.~  4. Venous occlusion precluding adequate access.~  5. Recent systemic illness.~6. Renal failure defined as serum creatinine \> 2 times higher than the upper limit of normal.~7. Liver dysfunction defined as alanine aminotransferase or aspartate aminotransferase \> 3 times higher than the upper limit of normal.~8. Thrombocytopenia defined as a platelet count \< 50 000 cells/µL.~9. Leukopenia defined as white blood cells \< 2500 cells/µL.

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 120 Months
- Healthy Volunteers: f

Study Arms:
- Sildenafil (Type: ACTIVE_COMPARATOR): Pharmacokinetic and hemodynamic evaluation following sildenafil administration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Research Study to Examine the Difference Between Local Anesthetics Alone and Local Anesthetics Plus Steroids in the Treatment of Chronic Headache

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, age 18-65 inclusive~* Patients who have chronic daily headache (15 or more headache days per month) for at least 3 months prior to enrollment in the study.~* Headache level should be 5/10 or more at time of GON block.~* Patients should have posterior cervical muscle tenderness at time of nerve block.~Exclusion Criteria:~* Patients who had surgery or any other invasive procedure in the occipital area.~* Patients with abnormal sensory findings on examination or any known neurological disease that may affect skin sensation (peripheral neuropathy, multiple sclerosis, stroke, etc).~* Patients diagnosed with cluster headache~* Patients with skin diseases that may affect skin sensation.~* Patients who are cognitively impaired.~* Patients with significant psychiatric disorder that may affect their understanding of the study protocol and/or their cooperation with the investigators.~* Patients who are pregnant or breast-feeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lidocaine 2%, Bupivicaine 0.5% and saline (Type: ACTIVE_COMPARATOR): Adult patients with CDH, and headache of at least moderate intensity at time of treatment, were randomized to receive bilateral GONB and trigger point injections in the cervical paraspinal and the trapezius muscles bilaterally.
- Lidocaine 2%, Bupivicaine 0.5% and triamcinolone 40 mg (Type: ACTIVE_COMPARATOR): Adult patients with CDH, and headache of at least moderate intensity at time of treatment, were randomized to receive bilateral GONB and trigger point injections in the cervical paraspinal and the trapezius muscles bilaterally.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cytoreduction and Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Metastatic disease to the peritoneum from colon or rectum (at least two isolated sites of disease)~* verified primary tumor of adenocarcinoma of the colon or rectum~* Potential resectability as judged by the treating surgeon~* Patient is available for follow-up according to the study protocol~* Signed informed consent~Exclusion Criteria:~* Extraabdominal metastases or liver metastases~* Paraaortic or other inoperable lymph node metastases~* Clear indication for surgery only (such as obstruction, bleeding or peritonitis)~* Prior treatment of either arm in the study~* Clinical or histopathological diagnosis of Peritoneal Pseudomyxoma~* Age \> 80~* Contraindications for chemotherapy~* Pregnancy or breastfeeding~* Ongoing infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Arm A: CRS plus postop intraperitoneal chemotherapy. (Type: EXPERIMENTAL): Cytoreductive surgery and postoperative intraperitoneal chemotherapy.
- Arm B: Systemic chemotherapy alone (Type: ACTIVE_COMPARATOR): Systemic chemotherapy alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete